AVIGA3 (Cohort 2.0)
NCT: NCT07255859 · RECRUITING
Brief Summary
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
Frequently Asked Questions
What is AVIGA3 (Cohort 2.0)?
AVIGA3 (Cohort 2.0) is a clinical trial registered under NCT07255859. Current status: RECRUITING.
What is the status of NCT07255859?
The current status of NCT07255859 (AVIGA3 (Cohort 2.0)) is: RECRUITING.
When did AVIGA3 (Cohort 2.0) start?
AVIGA3 (Cohort 2.0) started on 2025-06-16.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.